BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

800 related articles for article (PubMed ID: 19428840)

  • 1. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs.
    Kyriakis CS; De Vleeschauwer A; Barbé F; Bublot M; Van Reeth K
    Vaccine; 2009 Apr; 27(16):2258-64. PubMed ID: 19428840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
    Pavlova SP; Veits J; Keil GM; Mettenleiter TC; Fuchs W
    Vaccine; 2009 Jan; 27(5):773-85. PubMed ID: 19041677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and use of fowlpox vectored vaccines for avian influenza.
    Bublot M; Pritchard N; Swayne DE; Selleck P; Karaca K; Suarez DL; Audonnet JC; Mickle TR
    Ann N Y Acad Sci; 2006 Oct; 1081():193-201. PubMed ID: 17135511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Level of protection of chickens against highly pathogenic H5 avian influenza virus with Newcastle disease virus based live attenuated vector vaccine depends on homology of H5 sequence between vaccine and challenge virus.
    Römer-Oberdörfer A; Veits J; Helferich D; Mettenleiter TC
    Vaccine; 2008 May; 26(19):2307-13. PubMed ID: 18395947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
    Jadhao SJ; Lee CW; Sylte M; Suarez DL
    Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Live vaccination with an H5-hemagglutinin-expressing infectious laryngotracheitis virus recombinant protects chickens against different highly pathogenic avian influenza viruses of the H5 subtype.
    Pavlova SP; Veits J; Mettenleiter TC; Fuchs W
    Vaccine; 2009 Aug; 27(37):5085-90. PubMed ID: 19573638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions.
    Veits J; Römer-Oberdörfer A; Helferich D; Durban M; Suezer Y; Sutter G; Mettenleiter TC
    Vaccine; 2008 Mar; 26(13):1688-96. PubMed ID: 18291561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of a recombinant fowl poxvirus vaccine containing an avian influenza hemagglutinin gene to provide consistent protection against influenza in chickens preimmunized with a fowl pox vaccine.
    Swayne DE; Beck JR; Kinney N
    Avian Dis; 2000; 44(1):132-7. PubMed ID: 10737653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus.
    Kapczynski DR; Esaki M; Dorsey KM; Jiang H; Jackwood M; Moraes M; Gardin Y
    Vaccine; 2015 Feb; 33(9):1197-205. PubMed ID: 25613723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of recombinant fowl poxvirus vaccine in protecting chickens against a highly pathogenic Mexican-origin H5N2 avian influenza virus.
    Swayne DE; Beck JR; Mickle TR
    Avian Dis; 1997; 41(4):910-22. PubMed ID: 9454926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further evidence of antigenic drift and protective efficacy afforded by a recombinant HVT-H5 vaccine against challenge with two antigenically divergent Egyptian clade 2.2.1 HPAI H5N1 strains.
    Rauw F; Palya V; Van Borm S; Welby S; Tatar-Kis T; Gardin Y; Dorsey KM; Aly MM; Hassan MK; Soliman MA; Lambrecht B; van den Berg T
    Vaccine; 2011 Mar; 29(14):2590-600. PubMed ID: 21292007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced protective efficacy of H5 subtype avian influenza DNA vaccine with codon optimized HA gene in a pCAGGS plasmid vector.
    Jiang Y; Yu K; Zhang H; Zhang P; Li C; Tian G; Li Y; Wang X; Ge J; Bu Z; Chen H
    Antiviral Res; 2007 Sep; 75(3):234-41. PubMed ID: 17451817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
    Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
    Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prior infection with an H1N1 swine influenza virus partially protects pigs against a low pathogenic H5N1 avian influenza virus.
    Van Reeth K; Braeckmans D; Cox E; Van Borm S; van den Berg T; Goddeeris B; De Vleeschauwer A
    Vaccine; 2009 Oct; 27(45):6330-9. PubMed ID: 19840669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prime-boost vaccination with a fowlpox vector and an inactivated avian influenza vaccine is highly immunogenic in Pekin ducks challenged with Asian H5N1 HPAI.
    Steensels M; Bublot M; Van Borm S; De Vriese J; Lambrecht B; Richard-Mazet A; Chanavat-Bizzini S; Duboeuf M; Le Gros FX; van den Berg T
    Vaccine; 2009 Jan; 27(5):646-54. PubMed ID: 19056442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.
    Itoh Y; Ozaki H; Tsuchiya H; Okamoto K; Torii R; Sakoda Y; Kawaoka Y; Ogasawara K; Kida H
    Vaccine; 2008 Jan; 26(4):562-72. PubMed ID: 18164788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prime-boost vaccination with recombinant H5-fowlpox and Newcastle disease virus vectors affords lasting protection in SPF Muscovy ducks against highly pathogenic H5N1 influenza virus.
    Niqueux E; Guionie O; Amelot M; Jestin V
    Vaccine; 2013 Aug; 31(38):4121-8. PubMed ID: 23845804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of an inactivated and a fowlpox-vectored vaccine in Muscovy ducks against an Asian H5N1 highly pathogenic avian influenza viral challenge.
    Steensels M; Van Borm S; Lambrecht B; De Vriese J; Le Gros FX; Bublot M; van den Berg T
    Avian Dis; 2007 Mar; 51(1 Suppl):325-31. PubMed ID: 17494576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection of chickens against highly lethal H5N1 and H7N1 avian influenza viruses with a recombinant fowlpox virus co-expressing H5 haemagglutinin and N1 neuraminidase genes.
    Qiao CL; Yu KZ; Jiang YP; Jia YQ; Tian GB; Liu M; Deng GH; Wang XR; Meng QW; Tang XY
    Avian Pathol; 2003 Feb; 32(1):25-32. PubMed ID: 12745375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.